Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders


Author index

Page Path
HOME > Browse Articles > Author index
Demetrius M. Maraganore 1 Article
Rationale for Therapeutic Silencing of Alpha-Synuclein in Parkinson’s Disease
Demetrius M. Maraganore
J Mov Disord. 2011;4(1):1-7.
  • 12,748 View
  • 68 Download
  • 8 Citations
AbstractAbstract PDF

The purpose of this paper is to provide the rationale for therapeutic silencing of the alpha-synuclein gene (SNCA) in Parkinson’s disease (PD). The paper reviews the public health significance of PD; the causal links between rare SNCA variants and familial PD; the association of common SNCA variants and PD susceptibility; the association of SNCA variants also with age at onset and motor and cognitive outcomes in PD; therapeutic strategies targeting SNCA in PD; and preliminary findings and considerations on small interfering RNA-based therapies and PD.


Citations to this article as recorded by  
  • Antisense therapies in neurological diseases
    Jean-Baptiste Brunet de Courssou, Alexandra Durr, David Adams, Jean-Christophe Corvol, Louise-Laure Mariani
    Brain.2022; 145(3): 816.     CrossRef
  • Parkinson's disease: Alterations in iron and redox biology as a key to unlock therapeutic strategies
    L. Ma, M. Gholam Azad, M. Dharmasivam, V. Richardson, R.J. Quinn, Y. Feng, D.L. Pountney, K.F. Tonissen, G.D. Mellick, I. Yanatori, D.R. Richardson
    Redox Biology.2021; 41: 101896.     CrossRef
  • Translation of the intrinsically disordered protein α-synuclein is inhibited by a small molecule targeting its structured mRNA
    Peiyuan Zhang, Hye-Jin Park, Jie Zhang, Eunsung Junn, Ryan J. Andrews, Sai Pradeep Velagapudi, Daniel Abegg, Kamalakannan Vishnu, Matthew G. Costales, Jessica L. Childs-Disney, Alexander Adibekian, Walter N. Moss, M. Maral Mouradian, Matthew D. Disney
    Proceedings of the National Academy of Sciences.2020; 117(3): 1457.     CrossRef
  • Small molecule recognition of disease-relevant RNA structures
    Samantha M. Meyer, Christopher C. Williams, Yoshihiro Akahori, Toru Tanaka, Haruo Aikawa, Yuquan Tong, Jessica L. Childs-Disney, Matthew D. Disney
    Chemical Society Reviews.2020; 49(19): 7167.     CrossRef
  • Dysregulation of the causative genes for hereditary parkinsonism in the midbrain in Parkinson's disease
    Yun Joong Kim, Junbeom Jeon, Jaemoon Shin, Nan Young Kim, Jeong Hoon Hong, Jae-Min Oh, SangKyoon Hong, Yeo Jin Kim, Young-Eun Kim, Suk Yun Kang, Hyeo-Il Ma, Unjoo Lee, Jeehee Yoon
    Movement Disorders.2017; 32(8): 1211.     CrossRef
  • Anionic liposomes for small interfering ribonucleic acid (siRNA) delivery to primary neuronal cells: Evaluation of alpha-synuclein knockdown efficacy
    Michele Schlich, Francesca Longhena, Gaia Faustini, Caitriona M. O’Driscoll, Chiara Sinico, Anna Maria Fadda, Arianna Bellucci, Francesco Lai
    Nano Research.2017; 10(10): 3496.     CrossRef
  • Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders
    Elvira Valera, Brian Spencer, Eliezer Masliah
    Neurotherapeutics.2016; 13(1): 179.     CrossRef
  • Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders
    Hayate Javed, Sindhu A Menon, Karima M Al-Mansoori, Abdelmojib Al-Wandi, Nour K Majbour, Mustafa T Ardah, Shiji Varghese, Nishant N Vaikath, M Emdadul Haque, Mimoun Azzouz, Omar MA El-Agnaf
    Molecular Therapy.2016; 24(4): 746.     CrossRef

JMD : Journal of Movement Disorders